Lung Cancer
Conditions
Keywords
recurrent non-small cell lung cancer, stage I non-small cell lung cancer, stage II non-small cell lung cancer, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer
Brief summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood samples from patients with non-small cell lung cancer and from healthy volunteers.
Detailed description
OBJECTIVES: * Measure plasma cathepsin D levels in patients with non-small cell lung cancer and in healthy volunteers using mass spectometry. * Measure fatty acid synthase levels in these patients and healthy volunteers using mass spectometry. OUTLINE: Blood samples are collected from patients and healthy volunteers to measure the levels of cathepsin D and fatty acid synthase by proteomic profiling and mass spectrometry.
Interventions
OTHERMass Spectrometry
Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
Sponsors
University of Minnesota
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Non-Small Cell Lung Cancer Patients * Documented diagnosis of non-small cell lung cancer, any stage and any time point in the course of treatment (i.e., at diagnosis, during any treatment, and during post treatment surveillance) * Measurable disease by CT scan within the past 4 weeks Healthy volunteer * Non-smoking, defined as \< 5 packs/year history of smoking and cessation of smoking ≥ 6 months ago OR a never smoker * Not regularly exposed (i.e., daily) to second-hand smoke
Exclusion criteria
* Severe underlying lung disease (i.e., chronic obstructive pulmonary disease with FEV\_1 \< 1.0 L, pulmonary fibrosis, bronchiectasis, cystic fibrosis, etc.) as determined by enrolling researcher. Written consent must be given for both subjects and controls.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Levels of cathepsin D | At Routine Follow-Up | Measure plasma CD levels in patients with non-small cell lung cancer and non-smoker healthy controls using mass spectrometry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Levels of fatty acid synthase (FAS) | At Routine Follow-Up | Measure FAS levels in patients with non-small cell lung cancer and non-smoker healthy controls using mass spectrometry. |
| Global microRNA expression | At Routine Follow-Up | Measure global microRNA expression by microarray analysis using Illumina probes. |
Countries
United States
Outcome results
None listed